Literature DB >> 7249373

Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia.

R Berger, G P Smit, S A Stoker-de Vries, M Duran, D Ketting, S K Wadman.   

Abstract

A patient is described with type I tyrosinemia characterized by urinary excretion of succinylacetone together with increased excretion of tyrosine, p-hydroxyphenyllactic, p-hydroxyphenylpyruvic and p-hydroxyphenylacetic acids. Fumarylacetoacetase was measured in a liver biopsy and found to be very low compared to control liver. Furthermore the mass spectra of succinylacetone and fumarylacetoacetate (methoxime-TMS derivatives) are reported. Control jejunal mucosa, leucocytes and fibroblasts showed no enzyme activity; hence the prenatal diagnosis of this disease by measuring the fumarylacetoacetase activity in cultured amniotic fluid cells is not possible at present.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7249373     DOI: 10.1016/0009-8981(81)90225-4

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  15 in total

1.  Tyrosinaemia type III: immunochemical studies on 4-hydroxyphenylpyruvic acid dioxygenase and molecular cloning of cDNA for the enzyme.

Authors:  F Endo; H Awata; A Tanoue; Y Eda; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

Review 2.  Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem.

Authors:  F J van Spronsen; R Berger; G P Smit; J B de Klerk; M Duran; C M Bijleveld; H van Faassen; M J Slooff; H S Heymans
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

3.  A new variant form of hypertyrosinaemia due to 4-hydroxyphenylpyruvic acid oxidase deficiency.

Authors:  F Endo; A Kitano; I Uehara; N Nagata; I Matsuda; T Shinka; T Kuhara; I Matsumoto
Journal:  J Inherit Metab Dis       Date:  1982       Impact factor: 4.982

4.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

5.  Prenatal diagnosis of tyrosinaemia type I by use of stable isotope dilution mass spectrometry.

Authors:  C Jakobs; E A Kvittingen; R Berger; A Haagen; W Kleijer; M Niermeijer
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

6.  Putative genetic deficiency of 4-hydroxyphenylpyruvic acid dioxygenase in mice: a murine model for hereditary tyrosinaemia type III.

Authors:  F Endo; H Katoh; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

7.  A murine model for type III tyrosinemia: lack of immunologically detectable 4-hydroxyphenylpyruvic acid dioxygenase enzyme protein in a novel mouse strain with hypertyrosinemia.

Authors:  F Endo; H Katoh; S Yamamoto; I Matsuda
Journal:  Am J Hum Genet       Date:  1991-04       Impact factor: 11.025

8.  Persistent succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type I.

Authors:  M Tuchman; D K Freese; H L Sharp; C B Whitley; M L Ramnaraine; R A Ulstrom; J S Najarian; N Ascher; N R Buist; A B Terry
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

Review 9.  Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells.

Authors:  F Endo; M S Sun
Journal:  J Inherit Metab Dis       Date:  2002-05       Impact factor: 4.982

10.  Hereditary tyrosinaemia type I: a long-term study of the relationship between the urinary excretions of succinylacetone and delta-aminolevulinic acid.

Authors:  H Schierbeek; G J Beukeveld; H van Faassen; F J van Spronsen; K Bijsterveld; E E Venekamp-Hoolsema; B G Wolthers; G P Smit
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.